Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Abstract
In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti–interleukin-17A monoclonal antibody, in such patients.

This publication has 32 references indexed in Scilit: